Thorn Bioscience

Thorn Bioscience is a veterinary biotechnology company that specialized in the development of reproductive pharmaceuticals for the equine industry. The company's primary achievement was the development and FDA approval of SucroMate Equine, a sustained-release deslorelin acetate injection used to synchronize and induce ovulation in mares. This product utilized a proprietary delivery technology designed to provide controlled release of the active peptide. In October 2010, the trade and assets of Thorn Bioscience were acquired by Dechra Pharmaceuticals for approximately 12 million dollars. Following the acquisition, the company's lead product became a core part of Dechra's equine endocrine portfolio. Thorn Bioscience was headquartered in Louisville, Kentucky, and focused its research and development on addressing unmet needs in animal reproduction.